Findings related to effectiveness ( treatment discontinuation , quality of life , and neurocognitive improvements ) were generally consistent with those observed in non-Chinese population s. No new safety signals specific for Chinese population s were raised for olanzapine .
Chinese and non-Chinese population s with schizophrenia or bipolar disorder treated with olanzapine display broadly similar responses .
BACKGROUND Despite the burden of schizophrenia and bipolar disorder in the Chinese population , country-specific data to guide practitioners regarding antipsychotic therapy are lacking .
Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania. Results from a randomized controlled trial.
INTRODUCTION The objectives of this study were to determine the economic , clinical , and quality -of-life outcomes associated with olanzapine treatment in patients diagnosed with mania . METHODS Patients with a diagnosis of bipolar I disorder with manic or mixed episodes were enrolled in a r and omized controlled trial . The study design comprised a 3-week acute phase followed by a 49-week open label extension . In the open label extension , the use of lithium and fluoxetine was permitted for patients who experienced breakthrough symptoms . Clinical , economic , and quality -of-life outcomes of treatment were assessed . RESULTS During the acute phase , olanzapine patients experienced a statistically significant greater mean improvement from baseline on the Y-MRS total score compared to the placebo patients . In the open label extension , patients experienced a statistically significant mean change of 11.8 units on the Y-MRS from the end of the acute phase . When compared to costs incurred in the previous 12 months of therapy , patients experienced savings of almost $ 900 per month during the 49 weeks of olanzapine therapy . These cost savings were largely driven by reductions in in-patient costs during the open label extension . Health-related quality of life improvements measured by the SF-36 were seen on several dimensions both in the 3-week acute phase as well as in the 49-week open label extension . CONCLUSION From a clinical , economic , and quality -of-life outcomes st and point , olanzapine had a significant impact in the treatment of mania , and could be considered a cost-effective treatment option for use in this population if these findings are extrapolated to non- clinical trial population
Findings related to effectiveness ( treatment discontinuation , quality of life , and neurocognitive improvements ) were generally consistent with those observed in non-Chinese population s. No new safety signals specific for Chinese population s were raised for olanzapine .
Chinese and non-Chinese population s with schizophrenia or bipolar disorder treated with olanzapine display broadly similar responses .
BACKGROUND Despite the burden of schizophrenia and bipolar disorder in the Chinese population , country-specific data to guide practitioners regarding antipsychotic therapy are lacking .